CHICAGO -- Availability of a bevacizumab biosimilar for ophthalmic use could eliminate a lower-cost treatment option for a wide variety of off-label indications and add hundreds of millions of dollars ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results